Clinical trial
Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy
NCT02052661 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 18, 2014
- Completion date
- September 23, 2014
- Enrollment
- 301 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.